Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)

Inclusion Criteria: 1. Male gender 2. Age ≥18 years and ≤45 years 3. BMI ≥16 4. P. falciparum parasitaemia at any density 5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control group receiving AL only (N=50) 6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20) 7. Informed consent by participant Exclusion Criteria: 1. Enrolled in another clinical trial 2. Fever \>37.5°C (tympanic) or history of fever in the last 24 hours 3. Evidence of severe illness / danger signs or active infection other than malaria 4. Known allergy to study medications 5. Hb \<11 g/dL 6. Antimalarials taken within the last 2 weeks 7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days 8. Non-falciparum malaria co-infection 9. Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue phenazopyridine and co-trimoxazole. 10. History of severe chronic illness